Floatz logo

Inno-206

Palmar-plantar Erythrodysesthesia

Swiss Cancer InstitutePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Palmar-plantar Erythrodysesthesia cohort.

Asset / SponsorPhaseRating
Mecobalamin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3B
Dfn-15
Affiliated Hospital of Qinghai University
Phase 3B
Tazarotene
Dana-Farber Cancer Institute
Phase 2CCC
Nicotine
University of California, San Francisco
Phase 2CCC
ADVICOR COMPONENT NIACIN
First People's Hospital of Hangzhou
Phase 2CCC

View all 11 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →